Herrlinger, Ulrich;Tzaridis, Theophilos;Mack, Frederic;Steinbach, Joachim Peter;Schlegel, Uwe;Sabel, Michael;Hau, Peter;Kortmann, Rolf-Dieter;Krex, Dietmar;Grauer, Oliver;Goldbrunner, Roland;Schnell, Oliver;Bähr, Oliver;Uhl, Martin;Seidel, Clemens;Tabatabai, Ghazaleh;Kowalski, Thomas;Ringel, Florian;Schmidt-Graf, Friederike;Suchorska, Bogdana;Brehmer, Stefanie;Weyerbrock, Astrid;Renovanz, Miriam;Bullinger, Lars;Galldiks, Norbert;Vajkoczy, Peter;Misch, Martin;Vatter, Hartmut;Stuplich, Moritz;Schäfer, Niklas;Kebir, Sied;Weller, Johannes;Schaub, Christina;Stummer, Walter;Tonn, Jörg-Christian;Simon, Matthias;Keil, Vera C;Nelles, Michael;Urbach, Horst;Coenen, Martin;Wick, Wolfgang;Weller, Michael;Fimmers, Rolf;Schmid, Matthias;Hattingen, Elke;Pietsch, Torsten;Coch, Christoph;Glas, Martin.Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial..Lancet.2019.393.10172.678-688